LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Randox Showcases Latest Product Portfolio and Services at MEDLAB Middle East 2021

By LabMedica International staff writers
Posted on 23 Jun 2021
Print article
Image: Randox Showcases Latest Product Portfolio and Services at MEDLAB Middle East 2021 (Photo courtesy of Randox Laboratories)
Image: Randox Showcases Latest Product Portfolio and Services at MEDLAB Middle East 2021 (Photo courtesy of Randox Laboratories)
Randox Laboratories (Crumlin, UK) shared a wealth of new products and innovative technologies with the industry at the 2021 edition of MEDLAB Middle East.

Randox has developed a range of new tests for COVID-19 (SARS-CoV-2) targeting genes in line with WHO & CDC recommendations. Utilizing Patented Biochip Technology, with results available from the Vivalytic, Evidence Investigator and Randox Discovery, capable of detecting both SARS-CoV-2 and Sarbecovirus (confirmatory target), to report SARS-CoV-2 positive patient samples. The Vivalytic, Evidence Investigator and Randox Discovery platforms were on display at this year’s MEDLAB Middle East.

Randox also showcased its new benchtop lab - Randox Discovery - an exciting and unique analyzer consolidating molecular and immunoassay workflows onto one compact benchtop platform. The COVID-19 diagnostic analyzer is the first to combine sample preparation techniques including extraction, PCR & Biochip Technology. Simple and easy to use, the intuitive user-interface guides the operator through the entire testing process. Built with the user and laboratory in mind, a single operator is all that is required to run up to three fully automated discovery platforms increasing operator walkaway time and ensuring rapid turnaround time of three hours to first batch results.

In addition, Randox presented the RX series of clinical chemistry analyzers that offer the world’s most extensive dedicated clinical chemistry test menu comprising routine chemistries, specific proteins, lipids, therapeutic drugs, drugs of abuse, antioxidants, veterinary and diabetes testing. They guarantee real cost savings through consolidation of routine and specialized tests onto a single platform. The RX series analyzers - RX MISANO, RX MONACO, RX DAYTONA+,

RX IMOLA and RX MODENA - deliver excellence in patient care, offering unrivalled precision with excellent reagent CV ranges, providing laboratories with the upmost reliability, analyser uptime and accuracy of patient results. With their extensive test menu and versatile range of analyzers, the RX series presents the ultimate in performance, functionality and efficiency with testing capabilities to suit all laboratory sizes and types. Renowned for robust hardware and intuitive software, the RX series continues to revolutionize testing in a variety of laboratory types including; Clinical Laboratories, University & Research Institutes, Veterinary Laboratories and Food & Wine Testing Laboratories.

Related Links:
Randox Laboratories

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Cytomegalovirus Real-Time PCR Test
Quanty CMV Virus System
New
PSA Test
Humasis PSA Card

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.